ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024

ImmunityBio, Inc.

2025-Q1 EPS reported -$0.15 revenue$16,517,000

Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.
ANKTIVA unit sales volume grew 150% in Q1 2025 compared to Q4 2024, with March volume up 69% over February.
Nearly 200 urology practices are registering for ImmunityBio's recombinant BCG Expanded Access Program (EAP).
Positive long-term results from the QUILT 3.032 study showed highest cystectomy avoidance in NMIBC space.
ImmunityBio completed a $75 million equity financing in April 2025 to support operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.